Pharmacological Reviews Get Tables of Contents delivered automatically
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, K.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, K.
Right arrow Articles by Sugiyama, Y.

Vol. 50, Issue 3, 387-412, September 1998

Prediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the Liver

K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki and Y. Sugiyamaa

Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

I. Introduction
II. Drug-Drug Interactions Other Than Involving Metabolism
    A. Drug-drug interactions involving plasma protein binding
    B. Drug-drug interactions at the transport carrier
III. Drug-Drug Interactions Involving Metabolism in the Liver
    A. Examples of In Vivo Drug-Drug Interactions Involving P450 Metabolism
    B. Inhibition Mechanism of Drug Metabolism by P450
    C. Inhibition Patterns of Drug Metabolism
        1. Competitive Inhibition.
        2. Noncompetitive Inhibition.
        3. Uncompetitive Inhibition.
    D. Prediction of In Vivo Drug-Drug Interactions Based on In Vitro Data
        1. General Equations.
        2. The evaluation of the unbound concentration of the inhibitor in vivo.
    E. Examples of the Prediction of Drug-Drug Interactions Based on Literature Data
        1. Successful Cases of In Vitro/In Vivo Prediction.
        2. Interactions Predictable for the Objective Metabolic Pathway but not Predictable for the Overall Data.
        3. Interactions Not Predictable by In Vitro/In Vivo Scaling.
    F. Procedure for Predicting Inhibitory Effects of Coadministered Drugs on the Hepatic Metabolism of Other Drugs
    G. Mechanism-Based Inhibition
        1. Characteristics of Mechanism-Based Inhibition.
        2. Kinetic Analysis of Mechanism-Based Inhibition: Analysis of In Vitro Data.
        3. Prediction of In Vivo Interactions from In Vitro Data in the Case of Mechanism-Based Inhibition.
    H. Problems To Be Solved for the More Precise Prediction of Drug-Drug Interactions
        1. Estimation of the Tissue Unbound Concentration of the Inhibitor That Is Actively Transported into Hepatocytes.
        2. Evaluation of Drug-Drug Interactions Involving Drug Metabolism in the Gut.
References

a   Address for correspondence: Yuichi Sugiyama, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan, Phone: 81-3-5689-8094, Fax: 81-3-5800-6949, E-mail: sugiyama{at}seizai.f.u-tokyo.ac.jp.

0031-6997/98/5003-0387$03.00/0
PHARMACOLOGICAL REVIEWS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
X. Zhang, D. R. Jones, and S. D. Hall
Prediction of the Effect of Erythromycin, Diltiazem, and Their Metabolites, Alone and in Combination, on CYP3A4 Inhibition
Drug Metab. Dispos., January 1, 2009; 37(1): 150 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Ogasawara, M. Utoh, K. Nii, A. Ueda, T. Yoshikawa, T. Kume, and K. Fukuzaki
Effect of Oral Ketoconazole on Oral and Intravenous Pharmacokinetics of Simvastatin and Its Acid in Cynomolgus Monkeys
Drug Metab. Dispos., January 1, 2009; 37(1): 122 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Shou, M. Hayashi, Y. Pan, Y. Xu, K. Morrissey, L. Xu, and G. L. Skiles
Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction
Drug Metab. Dispos., November 1, 2008; 36(11): 2355 - 2370.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. Wang, L. J. Christopher, D. Cui, W. Li, R. Iyer, W. G. Humphreys, and D. Zhang
Identification of the Human Enzymes Involved in the Oxidative Metabolism of Dasatinib: An Effective Approach for Determining Metabolite Formation Kinetics
Drug Metab. Dispos., September 1, 2008; 36(9): 1828 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Kotsuma, T. Tokui, S. Freudenthaler, and K. Nishimura
Effects of Ketoconazole and Quinidine on Pharmacokinetics of Pactimibe and Its Plasma Metabolite, R-125528, in Humans
Drug Metab. Dispos., August 1, 2008; 36(8): 1505 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
O. A. Fahmi, T. S. Maurer, M. Kish, E. Cardenas, S. Boldt, and D. Nettleton
A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro
Drug Metab. Dispos., August 1, 2008; 36(8): 1698 - 1708.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. F. McGinnity, N. J. Waters, J. Tucker, and R. J. Riley
Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug Interactions
Drug Metab. Dispos., June 1, 2008; 36(6): 1126 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
I. Bachmakov, H. Glaeser, M. F. Fromm, and J. Konig
Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1
Diabetes, June 1, 2008; 57(6): 1463 - 1469.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Matsushima, K. Maeda, N. Ishiguro, T. Igarashi, and Y. Sugiyama
Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans
Drug Metab. Dispos., April 1, 2008; 36(4): 663 - 669.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
E. D. Kharasch, D. Mitchell, and R. Coles
Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity
J. Clin. Pharmacol., April 1, 2008; 48(4): 464 - 474.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. P. Kanebratt and T. B. Andersson
HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans
Drug Metab. Dispos., January 1, 2008; 36(1): 137 - 145.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Yamada, K. Maeda, E. Kamiyama, D. Sugiyama, T. Kondo, Y. Shiroyanagi, H. Nakazawa, T. Okano, M. Adachi, J. D. Schuetz, et al.
Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor
Drug Metab. Dispos., December 1, 2007; 35(12): 2166 - 2176.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. S. Brown, A. Chadwick, and J. B. Houston
Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination
Drug Metab. Dispos., November 1, 2007; 35(11): 2119 - 2126.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. Nakashima, H. Takama, Y. Ogasawara, T. Kawakami, T. Nishitoba, S. Hoshi, E. Uchida, and H. Tanaka
Effect of Cinacalcet Hydrochloride, a New Calcimimetic Agent, on the Pharmacokinetics of Dextromethorphan: In Vitro and Clinical Studies
J. Clin. Pharmacol., October 1, 2007; 47(10): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Fowler, S. M. Lennon, G. Hoffmann, and C. R. Rayner
Comments on "Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel"
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 422 - 423.
[Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Sudsakorn, J. Skell, D. A. Williams, T. J. O'Shea, and H. Liu
Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes
Drug Metab. Dispos., June 1, 2007; 35(6): 841 - 847.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. Zhao, C. A. Lee, and K. L. Kunze
Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A
Drug Metab. Dispos., May 1, 2007; 35(5): 704 - 712.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Seithel, S. Eberl, K. Singer, D. Auge, G. Heinkele, N. B. Wolf, F. Dorje, M. F. Fromm, and J. Konig
The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3
Drug Metab. Dispos., May 1, 2007; 35(5): 779 - 786.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Lu, G. T. Miwa, S. R. Prakash, L.-S. Gan, and S. K. Balani
A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data
Drug Metab. Dispos., January 1, 2007; 35(1): 79 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Hirano, K. Maeda, Y. Shitara, and Y. Sugiyama
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Drug Metab. Dispos., July 1, 2006; 34(7): 1229 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Y. Chien, A. Lucksiri, C. S. Ernest II, J. C. Gorski, S. A. Wrighton, and S. D. Hall
STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE
Drug Metab. Dispos., July 1, 2006; 34(7): 1208 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Ishiguro, K. Maeda, W. Kishimoto, A. Saito, A. Harada, T. Ebner, W. Roth, T. Igarashi, and Y. Sugiyama
PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS
Drug Metab. Dispos., July 1, 2006; 34(7): 1109 - 1115.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Petri, E. Bergman, P. Forsell, M. Hedeland, U. Bondesson, L. Knutson, and H. Lennernas
FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL
Drug Metab. Dispos., July 1, 2006; 34(7): 1182 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Shimizu, K. Akimoto, T. Yoshimura, T. Niwa, K. Kobayashi, M. Tsunoo, and K. Chiba
AUTOINDUCTION OF MKC-963 [(R)-1-(1-CYCLOHEXYLETHYLAMINO)-4-PHENYLPHTHALAZINE] METABOLISM IN HEALTHY VOLUNTEERS AND ITS RETROSPECTIVE EVALUATION USING PRIMARY HUMAN HEPATOCYTES AND CDNA-EXPRESSED ENZYMES
Drug Metab. Dispos., June 1, 2006; 34(6): 950 - 954.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners
IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION
Drug Metab. Dispos., June 1, 2006; 34(6): 1055 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. F. McGinnity, J. Tucker, S. Trigg, and R. J. Riley
PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES
Drug Metab. Dispos., November 1, 2005; 33(11): 1700 - 1707.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Zhang, T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. G. Humphreys
IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION
Drug Metab. Dispos., November 1, 2005; 33(11): 1729 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Hirano, K. Maeda, H. Hayashi, H. Kusuhara, and Y. Sugiyama
Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 876 - 882.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. Zhao, K. L. Kunze, and C. A. Lee
EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES
Drug Metab. Dispos., June 1, 2005; 33(6): 853 - 861.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Venkatakrishnan and R. S. Obach
IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE
Drug Metab. Dispos., June 1, 2005; 33(6): 845 - 852.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Shitara, M. Hirano, Y. Adachi, T. Itoh, H. Sato, and Y. Sugiyama
IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF CERIVASTATIN IN RATS
Drug Metab. Dispos., December 1, 2004; 32(12): 1468 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Iwata, Y. Tezuka, S. Kadota, A. Hiratsuka, and T. Watabe
IDENTIFICATION AND CHARACTERIZATION OF POTENT CYP3A4 INHIBITORS IN SCHISANDRA FRUIT EXTRACT
Drug Metab. Dispos., December 1, 2004; 32(12): 1351 - 1358.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. V. Balakin, S. Ekins, A. Bugrim, Y. A. Ivanenkov, D. Korolev, Y. V. Nikolsky, A. V. Skorenko, A. A. Ivashchenko, N. P. Savchuk, and T. Nikolskaya
KOHONEN MAPS FOR PREDICTION OF BINDING TO HUMAN CYTOCHROME P450 3A4
Drug Metab. Dispos., October 1, 2004; 32(10): 1183 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. T. Donato, N. Jimenez, J. V. Castell, and M. J. Gomez-Lechon
FLUORESCENCE-BASED ASSAYS FOR SCREENING NINE CYTOCHROME P450 (P450) ACTIVITIES IN INTACT CELLS EXPRESSING INDIVIDUAL HUMAN P450 ENZYMES
Drug Metab. Dispos., July 1, 2004; 32(7): 699 - 706.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. Zhou, E. Chan, S.-Q. Pan, M. Huang, and E. J. D. Lee
Pharmacokinetic Interactions of Drugs with St John's Wort
J Psychopharmacol, June 1, 2004; 18(2): 262 - 276.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. M. Jones, D. Hallifax, and J. B. Houston
QUANTITATIVE PREDICTION OF THE IN VIVO INHIBITION OF DIAZEPAM METABOLISM BY OMEPRAZOLE USING RAT LIVER MICROSOMES AND HEPATOCYTES
Drug Metab. Dispos., May 1, 2004; 32(5): 572 - 580.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Nozaki, H. Kusuhara, H. Endou, and Y. Sugiyama
Quantitative Evaluation of the Drug-Drug Interactions between Methotrexate and Nonsteroidal Anti-Inflammatory Drugs in the Renal Uptake Process Based on the Contribution of Organic Anion Transporters and Reduced Folate Carrier
J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 226 - 234.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
P. Lu, M. L. Schrag, D. E. Slaughter, C. E. Raab, M. Shou, and A. D. Rodrigues
MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR
Drug Metab. Dispos., November 1, 2003; 31(11): 1352 - 1360.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Geng
A METHOD FOR IDENTIFICATION OF INHIBITION MECHANISM AND ESTIMATION OF KI IN IN VITRO ENZYME INHIBITION STUDY
Drug Metab. Dispos., November 1, 2003; 31(11): 1456 - 1457.
[Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama
Impact of Drug Transporter Studies on Drug Discovery and Development
Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. M. Neal, K. L. Kunze, R. H. Levy, R. A. O'Reilly, and W. F. Trager
KIIV, AN IN VIVO PARAMETER FOR PREDICTING THE MAGNITUDE OF A DRUG INTERACTION ARISING FROM COMPETITIVE ENZYME INHIBITION
Drug Metab. Dispos., August 1, 2003; 31(8): 1043 - 1048.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Ito, K. Ogihara, S.-i. Kanamitsu, and T. Itoh
PREDICTION OF THE IN VIVO INTERACTION BETWEEN MIDAZOLAM AND MACROLIDES BASED ON IN VITRO STUDIES USING HUMAN LIVER MICROSOMES
Drug Metab. Dispos., July 1, 2003; 31(7): 945 - 954.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A.-C. Egnell, B. Houston, and S. Boyer
In Vivo CYP3A4 Heteroactivation Is a Possible Mechanism for the Drug Interaction between Felbamate and Carbamazepine
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1251 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Yao, K. L. Kunze, W. F. Trager, E. D. Kharasch, and R. H. Levy
Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19
Drug Metab. Dispos., May 1, 2003; 31(5): 565 - 571.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. M. Fogelman, G. Chen, J. A. Graf, P. Mertzanis, S. Byron, K. E. Culm, B. W. Granda, et al.
Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone
J. Clin. Pharmacol., April 1, 2003; 43(4): 414 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. M. Bertelsen, K. Venkatakrishnan, L. L. von Moltke, R. S. Obach, and D. J. Greenblatt
Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine
Drug Metab. Dispos., March 1, 2003; 31(3): 289 - 293.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Shitara, T. Itoh, H. Sato, A. P. Li, and Y. Sugiyama
Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A
J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 610 - 616.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Kajita, K. Inano, E. Fuse, T. Kuwabara, and H. Kobayashi
Effects of Olopatadine, a New Antiallergic Agent, on Human Liver Microsomal Cytochrome P450 Activities
Drug Metab. Dispos., December 1, 2002; 30(12): 1504 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Galetin, S. E. Clarke, and J. B. Houston
Quinidine and Haloperidol as Modifiers of CYP3A4 Activity: Multisite Kinetic Model Approach
Drug Metab. Dispos., December 1, 2002; 30(12): 1512 - 1522.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
F. Gao, D. L. Johnson, S. Ekins, J. Janiszewski, K. G. Kelly, R. D. Meyer, and M. West
Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50
J Biomol Screen, August 1, 2002; 7(4): 373 - 382.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Kuroha, A. Azumano, Y. Kuze, M. Shimoda, and E. Kokue
Effect of Multiple Dosing of Ketoconazole on Pharmacokinetics of Midazolam, a Cytochrome P-450 3A Substrate in Beagle Dogs
Drug Metab. Dispos., January 1, 2002; 30(1): 63 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Hidestrand, M. Oscarson, J. S. Salonen, L. Nyman, O. Pelkonen, M. Turpeinen, and M. Ingelman-Sundberg
CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes
Drug Metab. Dispos., November 1, 2001; 29(11): 1480 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. E. White and P. Manitpisitkul
Pharmacokinetic Theory of Cassette Dosing in Drug Discovery Screening
Drug Metab. Dispos., July 1, 2001; 29(7): 957 - 966.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Ishigami, K. Kawabata, W. Takasaki, T. Ikeda, T. Komai, K. Ito, and Y. Sugiyama
Drug Interaction Between Simvastatin and Itraconazole in Male and Female Rats
Drug Metab. Dispos., July 1, 2001; 29(7): 1068 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Ueda, Y. Kato, K. Komatsu, and Y. Sugiyama
Inhibition of Biliary Excretion of Methotrexate by Probenecid in Rats: Quantitative Prediction of Interaction from in Vitro Data
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1036 - 1043.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
A. Hemeryck, C. A. De Vriendt, and F. M. Belpaire
Metoprolol-Paroxetine Interaction in Human Liver Microsomes: Stereoselective Aspects and Prediction of the in Vivo Interaction
Drug Metab. Dispos., April 13, 2001; 29(5): 656 - 663.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
T. B. Andersson, H. Sjöberg, K.-J. Hoffmann, A. R. Boobis, P. Watts, R. J. Edwards, B. G. Lake, R. J. Price, A. B. Renwick, M. J. Gómez-Lechón, et al.
An Assessment of Human Liver-Derived in Vitro Systems to Predict the in Vivo Metabolism and Clearance of Almokalant
Drug Metab. Dispos., April 13, 2001; 29(5): 712 - 720.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
K. Yamano, K. Yamamoto, M. Katashima, H. Kotaki, S. Takedomi, H. Matsuo, H. Ohtani, Y. Sawada, and T. Iga
Prediction of Midazolam{---}cyp3a Inhibitors Interaction in the Human Liver from in Vivo/in Vitro Absorption, Distribution, and Metabolism Data
Drug Metab. Dispos., April 1, 2001; 29(4): 443 - 452.
[Abstract] [Full Text]